Plasma Glucagon-Like Peptide-1 and Tissue Characteristics of Coronary Plaque in Non-Diabetic Acute Coronary Syndrome Patients

Mitsuhashi, Takayuki; Hibi, Kiyoshi; Konishi, Masaaki; Maejima, Nobuhiko; Iwahashi, Noriaki; Tsukahara, Kengo; Kosuge, Masami; Ebina, Toshiaki; Umemura, Satoshi; Kimura, Kazuo

doi:10.1253/circj.cj-15-0718

Cited by 5 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AUC-GLP-1 values in the subjects in the present study ranged widely as in earlier studies 11 , 25 . Since there are no established data for a normal range of AUC-GLP-1 value during the OGTT, the extent of change in GLP-1 secretory capacity is difficult to determine by use of OGTT data.…”

Section: Discussionsupporting

confidence: 79%

“…They conducted the OGTT by using almost the same blood sampling protocol as that used in our study, and AUC-GLP-1 in the normal control group was 969 ± 34 (mean ± SD, pmol/l ⨯ min). Mitsuhashi et al 25 reported data for AUC-GLP-1 tertiles in non-diabetic patients with acute coronary syndrome (n = 84): AUC < 395 (290 ± 84), AUC 395–660 (493 ± 73), and AUC > 660 (1,668 ± 1,229). In their study, the group with AUC < 395 had more lipid-rich coronary plaque than that in the other groups.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, there have been few studies in which the relationship between plasma level of GLP-1 and atherosclerotic change in the coronary artery was examined. Recently, Mitsuhashi et al 25 examined GLP-1 secretion during the OGTT in patients with acute coronary syndrome (n = 85) and found that the percentage of lipid area in the plaque in a culprit vessel was significantly higher in patients with a low tertile of AUC-GLP-1 (290 ± 84). www.nature.com/scientificreports/ However, patients in the low AUC-GLP-1 tertile group were younger and had higher levels of LDL-cholesterol and plasma insulin than patients in the high AUC-GLP-1 tertile group.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis

Nagase

Tanno

Kouzu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Multiple factors regulate glucagon-like peptide-1 (GLP-1) secretion, but a group of apparently healthy subjects showed blunted responses of GLP-1 secretion in our previous study. In this study, we examined whether the reduction in GLP-1 secretory capacity is associated with increased extent of coronary artery stenosis in non-diabetic patients. Non-diabetic patients who were admitted for coronary angiography without a history of coronary interventions were enrolled. Coronary artery stenosis was quantified by Gensini score (GS), and GS ≥ 10 was used as an outcome variable based on its predictive value for cardiovascular events. The patients (mean age, 66.5 ± 8.8 years; 71% males, n = 173) underwent oral 75 g-glucose tolerant tests for determination of glucose, insulin and active GLP-1 levels. The area under the curve of plasma active GLP-1 (AUC-GLP-1) was determined as an index of GLP-1 secretory capacity. AUC-GLP-1 was not correlated with fasting glucose, AUC-glucose, serum lipids or indices of insulin sensitivity. In multivariate logistic regression analysis for GS ≥ 10, AUC-GLP-1 < median, age and hypertension were selected as explanatory variables, though fasting GLP-1 level was not selected. The findings suggest that reduction in GLP-1 secretory capacity is a novel independent risk factor of coronary stenosis.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis

Nagase

Tanno

Kouzu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Clinical studies have also shown the anti-fibrotic effects of GLP-1RAs. Reduced GLP-1 levels in plasma have been associated with atheroma instability and cardiac fibrosis in non-diabetic patients with ACS [ 188 ]. Initiating GLP-1RAs therapy shortly after a first AMI in patients with diabetes has been linked to a reduced risk of significant CV events [ 189 ].…”

Section: Novel Drugs and Their Anti-fibrotic Rolementioning

confidence: 99%

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications

Tudurachi,

Anghel,

Tudurachi

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Myocardial infarction (MI) often leads to heart failure (HF) through acute or chronic maladaptive remodeling processes. This establishes coronary artery disease (CAD) and HF as significant contributors to cardiovascular illness and death. Therefore, treatment strategies for patients with CAD primarily focus on preventing MI and lessening the impact of HF after an MI event. Myocardial fibrosis, characterized by abnormal extracellular matrix (ECM) deposition, is central to cardiac remodeling. Understanding these processes is key to identifying new treatment targets. Recent studies highlight SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1-RAs) as favorable options in managing type 2 diabetes due to their low hypoglycemic risk and cardiovascular benefits. This review explores inflammation’s role in cardiac fibrosis and evaluates emerging anti-diabetic medications’ effectiveness, such as SGLT2i, GLP1-RAs, and dipeptidyl peptidase-4 inhibitors (DPP4i), in preventing fibrosis in patients with diabetes post-acute MI. Recent studies were analyzed to identify effective medications in reducing fibrosis risk in these patients. By addressing these areas, we can advance our understanding of the potential benefits of anti-diabetic medications in reducing cardiac fibrosis post-MI and improve patient outcomes in individuals with diabetes at risk of HF.

show abstract

Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes

Okada¹,

Kikuchi²,

Kuji³

et al. 2022

Atherosclerosis

View full text Add to dashboard Cite

Plasma Glucagon-Like Peptide-1 and Tissue Characteristics of Coronary Plaque in Non-Diabetic Acute Coronary Syndrome Patients

Abstract: Low plasma GLP-1 during 75-g OGTT is associated with increased lipid content in non-diabetic patients with ACS, suggesting that plaque vulnerability is increased in this subgroup of patients.

Cited by 5 publications

References 39 publications

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications

Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes

Contact Info

Product

Resources

About